Surface Oncology Inc

Surface Oncology Inc. is a clinical-stage company based in Cambridge, Massachusetts. With 29 employees, the company focuses on developing next-generation cancer therapies. Surface Oncology specializes in immuno-oncology, aiming to overcome the limitations of existing immunotherapies. Their research centers on the tumor microenvironment (TME), a complex ecosystem surrounding tumors that often suppresses the immune system's ability to fight cancer. The company develops immune-enhancing antibody candidates that target both the innate and adaptive arms of the immune system, aiming to convert "cold" tumors, which are unresponsive to current therapies, into immune-active ones. Surface Oncology's approach is characterized by its multi-faceted strategy, targeting various factors and cells within the TME that hinder the anti-tumor immune response. This comprehensive approach distinguishes them from therapies that focus on a single component of the TME. The company leverages a world-class Scientific Advisory Board (SAB) to identify new targets and employs an aggressive antibody discovery process, generating diverse and highly-specific antibodies to thoroughly explore the intricacies of TME biology. For more information, visit Surface Oncology's website at surfaceoncology.com.